CD4 and myeloid sarcoma: Despite the increased response of EBNA-1-specific CD4 T cells with the Th1 phenotype in most MS patients, Grytten et al. found a 14% increase in cancer risk over the years among MS patients compared to the controls, especially in respiratory organs, urinary organs, and the CNS [174].